Global Oncology
Customize your policy alerts
Sign up for all Hawaii Medical Service Association (HMSA) policy alerts
Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs precertification and coverage of oncology drugs prescribed as single agents or regimens under the medical benefit, including oral drugs used as part of an oncology regimen. It applies to HMSA HMO, PPO, QUEST, and Medicare Advantage members, subject to member contract exclusions and applicable Medicare coverage rules.
Evdi and Decnupaz were added to the medical benefit drug list effective June 12, 2026.
Keytruda Qlex was added to the medical benefit drug list on May 18, 2026.
Rybrevant Faspro and Vykoura were added to the medical benefit drug list on March 13, 2026.
Alimta was removed and Favlyxa was added on April 14, 2026.
Lymphir was added to the medical benefit drug list on December 23, 2025.
The document history records removal of Imaavy, Aliqopa, and other previously listed products during 2025.
Several products were removed because they were oral therapies, indicating that the medical benefit list focuses on applicable non-oral administration products.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.